heart failure. N Engl J Med 2010; 363:2385. 24. Bloom H, Heeke B, Leon A, et al. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol 2006; 29:142. 25. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361:1329. https://www.uptodate.com/contents/cardiac-resynchronization-therapy-in-heart-failure-indications-and-choice-of-system/print 23/32 7/6/23, 10:50 AM Cardiac resynchronization therapy in heart failure: Indications and choice of system - UpToDate 26. Biton Y, Kutyifa V, Cygankiewicz I, et al. Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy. Circ Heart Fail 2016; 9:e002667. 27. Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008; 52:1834. 28. Stavrakis S, Lazzara R, Thadani U. The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis. J Cardiovasc Electrophysiol 2012; 23:163. 29. Sipahi I, Chou JC, Hyden M, et al. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J 2012; 163:260. 30. Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013; 34:3547. 31. Kang SH, Oh IY, Kang DY, et al. Cardiac resynchronization therapy and QRS duration: systematic review, meta-analysis, and meta-regression. J Korean Med Sci 2015; 30:24. 32. Friedman DJ, Al-Khatib SM, Dalgaard F, et al. Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials. Circulation 2023; 147:812. 33. Sipahi I, Carrigan TP, Rowland DY, et al. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med 2011; 171:1454. 34. Strauss DG, Selvester RH, Wagner GS. Defining left bundle branch block in the era of cardiac resynchronization therapy. Am J Cardiol 2011; 107:927. 35. Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart 2015; 101:1800. 36. Zusterzeel R, Selzman KA, Sanders WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med 2014; 174:1340. 37. Peterson PN, Greiner MA, Qualls LG, et al. QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. JAMA 2013; 310:617. https://www.uptodate.com/contents/cardiac-resynchronization-therapy-in-heart-failure-indications-and-choice-of-system/print 24/32 7/6/23, 10:50 AM Cardiac resynchronization therapy in heart failure: Indications and choice of system - UpToDate 38. Leong DP, H ke U, Delgado V, et al. Predictors of long-term benefit of cardiac resynchronization therapy in patients with right bundle branch block. Eur Heart J 2012; 33:1934. 39. Birnie DH, Ha A, Higginson L, et al. Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 2013; 6:1190. 40. Fantoni C, Kawabata M, Massaro R, et al. Right and left ventricular activation sequence in patients with heart failure and right bundle branch block: a detailed analysis using three- dimensional non-fluoroscopic electroanatomic mapping system. J Cardiovasc Electrophysiol 2005; 16:112. 41. Cunnington C, Kwok CS, Satchithananda DK, et al. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non- left bundle branch block QRS morphology: meta-analysis of randomised controlled trials. Heart 2015; 101:1456. 42. Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013; 368:1585. 43. Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005; 16:1160. 44. Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007; 357:2461. 45. Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013; 369:1395. 46. Yu CM, Chan JY, Zhang Q, et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 2009; 361:2123. 47. Chan JY, Fang F, Zhang Q, et al. Biventricular pacing is superior to right ventricular pacing in bradycardia patients with preserved systolic function: 2-year results of the PACE trial. Eur Heart J 2011; 32:2533. 48. Bhattacharya S, Abebe K, Simon M, et al. Role of cardiac resynchronization in end-stage heart failure patients requiring inotrope therapy. J Card Fail 2010; 16:931. 49. Adelstein E, Bhattacharya S, Simon MA, et al. Comparison of outcomes for patients with nonischemic cardiomyopathy taking intravenous inotropes versus those weaned from or never taking inotropes at cardiac resynchronization therapy. Am J Cardiol 2012; 110:857. 50. Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. https://www.uptodate.com/contents/cardiac-resynchronization-therapy-in-heart-failure-indications-and-choice-of-system/print 25/32 7/6/23, 10:50 AM Cardiac resynchronization therapy in heart failure: Indications and choice of system - UpToDate BMJ 2007; 335:925. 51. K ber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med 2016; 375:1221. 52. Saba S, Adelstein E, Wold N, et al. Influence of patients' age at implantation on mortality and defibrillator shocks. Europace 2017; 19:802. 53. Adelstein EC, Jain S, Wang NC, et al. Left Ventricular Dimensions Predict Risk of Appropriate Shocks but Not Mortality in Cardiac Resynchronization Therapy-Defibrillator Recipients with Left Bundle-Branch Block and Non-Ischemic Cardiomyopathy. Europace 2016. 54. Adelstein EC, Liu J, Jain S, et al. Clinical outcomes in cardiac resynchronization therapy- defibrillator recipients 80 years of age and older. Europace 2016; 18:420. 55. Witt CT, Kronborg MB, Nohr EA, et al. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy. Europace 2016; 18:413. 56. Adelstein E, Schwartzman D, Gorcsan J 3rd, Saba S. Predicting hyperresponse among pacemaker-dependent nonischemic cardiomyopathy patients upgraded to cardiac resynchronization. J Cardiovasc Electrophysiol 2011; 22:905. 57. Adelstein E, Schwartzman D, Bazaz R, et al. Outcomes in pacemaker-dependent patients upgraded from conventional pacemakers to cardiac resynchronization therapy- defibrillators. Heart Rhythm 2014; 11:1008. 58. Leyva F, Zegard A, Acquaye E, et al. Outcomes of Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy. J Am Coll Cardiol 2017; 70:1216. 59. Wang NC, Singh M, Adelstein EC, et al. New-onset left bundle branch block-associated idiopathic nonischemic cardiomyopathy and left ventricular ejection fraction response to guideline-directed therapies: The NEOLITH study. Heart Rhythm 2016; 13:933. 60. Rangavajla G, Mulukutla S, Thoma F, et al. Ventricular pacing and myocardial function in patient with congenital heart block. J Cardiovasc Electrophysiol 2021; 32:2684. 61. Chatterjee NA, Roka A, Lubitz SA, et al. Reduced appropriate implantable cardioverter- defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. Eur Heart J 2015; 36:2780. 62. Adelstein EC, Schwartzman D, Jain S, et al. Left ventricular dimensions predict risk of appropriate shocks but not mortality in cardiac resynchronization therapy-defibrillator recipients with left bundle-branch block and non-ischemic cardiomyopathy. Europace 2017; 19:1689. https://www.uptodate.com/contents/cardiac-resynchronization-therapy-in-heart-failure-indications-and-choice-of-system/print 26/32 7/6/23, 10:50 AM Cardiac resynchronization therapy in heart failure: Indications and choice of system - UpToDate 63. Sherazi S, Shah F, Kutyifa V, et al. Risk of Ventricular Tachyarrhythmic Events in Patients Who Improved Beyond Guidelines for a Defibrillator in MADIT-CRT. JACC Clin Electrophysiol 2019; 5:1172. 64. Bradfield JS, Shivkumar K. Cardiac resynchronization therapy-induced proarrhythmia: understanding preferential conduction within myocardial scars. Circ Arrhythm Electrophysiol 2014; 7:1000. 65. Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation 2012; 125:1928. 66. Nassif ME, Tang Y, Cleland JG, et al. Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials. Circ Heart Fail 2017; 10. 67. Cardiac Resynchronization Therapy with Defibrillation (CRT-D). Colorado Program for Patient Centered Decisions. https://patientdecisionaid.org/icd-crt-2/ (Accessed on June 14, 2023). 68. Gorcsan J 3rd. Finding pieces of the puzzle of nonresponse to cardiac resynchronization therapy. Circulation 2011; 123:10. 69. Fornwalt BK, Sprague WW, BeDell P, et al. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation 2010; 121:1985. 70. Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010; 122:1553. 71. Adelstein EC, Tanaka H, Soman P, et al. Impact of scar burden by single-photon emission computed tomography myocardial perfusion imaging on patient outcomes following cardiac resynchronization therapy. Eur Heart J 2011; 32:93. 72. Razak E, Kamireddy S, Saba S. Implantable cardioverter-defibrillators confer survival benefit in patients with chronic obstructive pulmonary disease. Pacing Clin Electrophysiol 2010; 33:1125. 73. Pun PH, Al-Khatib SM, Han JY, et al. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis 2014; 64:32. 74. Goldenberg I, Vyas AK, Hall WJ, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008; 51:288. 75. Adelstein EC, Saba S, Jain S, Wang NC. Severe chronic kidney disease is associated with poor survival after initial CRT-defibrillator tachyarrhythmia therapy. Pacing Clin Electrophysiol https://www.uptodate.com/contents/cardiac-resynchronization-therapy-in-heart-failure-indications-and-choice-of-system/print 27/32 7/6/23, 10:50 AM Cardiac resynchronization therapy in heart failure: Indications and choice of system - UpToDate 2020; 43:78. 76. Dasgupta A, Montalvo J, Medendorp S, et al. Increased complication rates of cardiac rhythm management devices in ESRD patients. Am J Kidney Dis 2007; 49:656. 77. Chung BB, Grinstein JS, Imamura T, et al. Biventricular Pacing Versus Right Ventricular Pacing in Patients Supported With LVAD. JACC Clin Electrophysiol 2021; 7:1003. 78. European Heart Rhythm Association, European Society of Cardiology, Heart Rhythm Society, et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm 2012; 9:1524. 79. Chung MK, Patton KK, Lau CP, et al. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm 2023. 80. Wang Y, Zhu H, Hou X, et al. Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy. J Am Coll Cardiol 2022; 80:1205. 81. Jastrz bski M, Kie basa G, Cano O, et al. Left bundle branch area pacing outcomes: the multicentre European MELOS study. Eur Heart J 2022; 43:4161. 82. Chen X, Ye Y, Wang Z, et al. Cardiac resynchronization therapy via left bundle branch pacing vs. optimized biventricular pacing with adaptive algorithm in heart failure with left bundle branch block: a prospective, multi-centre, observational study. Europace 2022; 24:807. 83. Vijayaraman P. Extraction of Left Bundle Branch Pacing Lead. JACC Clin Electrophysiol 2020; 6:903. 84. 2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Miti gation of Heart Failure https://www.hrsonline.org/2023-hrsaphrslahrs-guideline-cardiac-phy siologic-pacing-avoidance-and-mitigation-heart-failure (Accessed on June 05, 2023). 85. Ezelsoy M, Bayram M, Yazici S, et al. Surgical placement of left ventricular lead for cardiac resynchronisation therapy after failure of percutaneous attempt. Cardiovasc J Afr 2017; 28:19. 86. McALOON CJ, Anderson BM, Dimitri W, et al. Long-Term Follow-Up of Isolated Epicardial Left Ventricular Lead Implant Using a Minithoracotomy Approach for Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol 2016; 39:1052. 87. Koos R, Sinha AM, Markus K, et al. Comparison of left ventricular lead placement via the coronary venous approach versus lateral thoracotomy in patients receiving cardiac resynchronization therapy. Am J Cardiol 2004; 94:59. 88. Doll N, Piorkowski C, Czesla M, et al. Epicardial versus transvenous left ventricular lead placement in patients receiving cardiac resynchronization therapy: results from a https://www.uptodate.com/contents/cardiac-resynchronization-therapy-in-heart-failure-indications-and-choice-of-system/print 28/32 7/6/23, 10:50 AM Cardiac resynchronization therapy in heart failure: Indications and choice of system - UpToDate randomized prospective study. Thorac Cardiovasc Surg 2008; 56:256. 89. Hummel JD, Coppess MA, Osborn JS, et al. Real-World Assessment of Acute Left Ventricular Lead Implant Success and Complication Rates: Results from the Attain Success Clinical Trial. Pacing Clin Electrophysiol 2016; 39:1246. Topic 3475 Version 41.0 https://www.uptodate.com/contents/cardiac-resynchronization-therapy-in-heart-failure-indications-and-choice-of-system/print 29/32 7/6/23, 10:50 AM Cardiac resynchronization therapy in heart failure: Indications and choice of system - UpToDate GRAPHICS Indications for referral for CRT for patients in sinus rhythm with LVEF 35% CRT: cardiac resynchronization therapy; LVEF: left ventricular ejection fraction; LBBB: left bundle branch block than LBBB; NYHA: New York Heart Association. Most patients with an LVEF 35% with an indication for CRT also have an indication for an implantable card choosing between a pacemaker (CRT-P) and a combined CRT-ICD (CRT-D). Graphic 115693 Version 2.0 https://www.uptodate.com/contents/cardiac-resynchronization-therapy-in-heart-failure-indications-and-choice-of-system/print 30/32 7/6/23, 10:50 AM Cardiac resynchronization therapy in heart failure: Indications and choice of system - UpToDate Indications for CRT in patients in sinus rhythm with LVEF between 35 and 50% CRT: cardiac resynchronization therapy; LVEF: left ventricular ejection fraction; LBBB: left bundle branch block QRS pattern on ECG; NYHA: New York Heart Association. Graphic 115692 Version 1.0 https://www.uptodate.com/contents/cardiac-resynchronization-therapy-in-heart-failure-indications-and-choice-of-system/print 31/32 7/6/23, 10:50 AM Cardiac resynchronization therapy in heart failure: Indications and choice of system - UpToDate Contributor Disclosures Evan Adelstein, MD No relevant financial relationship(s) with ineligible companies to disclose. Samir Saba, MD Grant/Research/Clinical Trial Support: Abbott [Implantable cardiac monitors in post-MI patients]. Consultant/Advisory Boards: Boston Scientific [Design of devices and clinical trials around AF ablation]; Medtronic [Use of temporary pacemakers in specific patient populations (eg, post-TAVR)]. All of the relevant financial relationships listed have been mitigated. Frederick Masoudi, MD, MSPH, FACC, FAHA Consultant/Advisory Boards: Bristol Meyers Squibb [Hypertrophic cardiomyopathy]; Colorado Prevention Center [Diabetes trial steering committee, study sponsor, Better Therapeutics]; TurningPoint [Utilization policy review]. Other Financial Interest: American College of Cardiology [Cardiovascular disease]; Massachusetts Medical Society [Cardiovascular disease]. All of the relevant financial relationships listed have been mitigated. Todd F Dardas, MD, MS No relevant financial relationship(s) with ineligible companies to disclose. Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence. Conflict of interest policy https://www.uptodate.com/contents/cardiac-resynchronization-therapy-in-heart-failure-indications-and-choice-of-system/print 32/32